Patients
toxicity
ONCOLOGY, RCC
Between October 2017 and August 2020, 45 patients were enrolled (8 patients in phase I and 37 patients in phase II) across five sites within the University of Colorado/UCHealth system. A total of 40 patients were treated at the RP2D and were evaluable for PFS and OS, and 38 patients were evaluable for response (CONSORT diagram and patient disposition. DLT, dose-limiting toxicity; RP2D, recommended phase II dose; P, pembrolizumab; C, cabozantinib.Baseline characteristicsAbbreviations: CPI, checkpoint inhibitor; ECOG, Eastern Cooperative Oncology Group performance status; IMDC, International Metastatic RCC Database Consortium; IQR, interquartile range; VEGFRi, vascular endothelial growth factor receptor inhibitor.